GSA Capital Partners LLP Purchases 7,078 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

GSA Capital Partners LLP lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 441.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,682 shares of the company's stock after purchasing an additional 7,078 shares during the period. GSA Capital Partners LLP's holdings in Neurocrine Biosciences were worth $1,000,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences in the 2nd quarter worth $28,000. Innealta Capital LLC acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth $30,000. New Covenant Trust Company N.A. acquired a new stake in Neurocrine Biosciences during the 1st quarter worth $32,000. EdgeRock Capital LLC acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth $35,000. Finally, Plato Investment Management Ltd acquired a new stake in Neurocrine Biosciences during the 1st quarter worth $41,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $5.44 during midday trading on Friday, reaching $117.44. 1,255,345 shares of the company's stock were exchanged, compared to its average volume of 867,191. Neurocrine Biosciences, Inc. has a 52 week low of $107.84 and a 52 week high of $157.98. The firm has a market cap of $11.89 billion, a price-to-earnings ratio of 31.49 and a beta of 0.35. The stock's 50-day simple moving average is $118.50 and its 200 day simple moving average is $132.66.

Analysts Set New Price Targets

Several analysts recently commented on the company. Jefferies Financial Group raised their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a "buy" rating in a research note on Monday, August 19th. JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. Guggenheim lifted their price target on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Royal Bank of Canada dropped their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. Finally, Raymond James reissued an "outperform" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.